ATE430746T1 - Crf-rezeptor-antagonisten und zugehörige verfahren - Google Patents

Crf-rezeptor-antagonisten und zugehörige verfahren

Info

Publication number
ATE430746T1
ATE430746T1 AT05814807T AT05814807T ATE430746T1 AT E430746 T1 ATE430746 T1 AT E430746T1 AT 05814807 T AT05814807 T AT 05814807T AT 05814807 T AT05814807 T AT 05814807T AT E430746 T1 ATE430746 T1 AT E430746T1
Authority
AT
Austria
Prior art keywords
receptor antagonists
crf receptor
associated methods
crf
pharmaceutically acceptable
Prior art date
Application number
AT05814807T
Other languages
English (en)
Inventor
Marion Lanier
Manisha Moorjani
John TELLEW
John P Williams
Original Assignee
Smithkline Beecham Cork Ltd
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Cork Ltd, Neurocrine Biosciences Inc filed Critical Smithkline Beecham Cork Ltd
Application granted granted Critical
Publication of ATE430746T1 publication Critical patent/ATE430746T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT05814807T 2004-10-19 2005-10-17 Crf-rezeptor-antagonisten und zugehörige verfahren ATE430746T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62001204P 2004-10-19 2004-10-19
PCT/US2005/037295 WO2006044821A1 (en) 2004-10-19 2005-10-17 Crf receptor antagonists and methods relating thereto

Publications (1)

Publication Number Publication Date
ATE430746T1 true ATE430746T1 (de) 2009-05-15

Family

ID=35696119

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05814807T ATE430746T1 (de) 2004-10-19 2005-10-17 Crf-rezeptor-antagonisten und zugehörige verfahren

Country Status (7)

Country Link
US (1) US7652035B2 (de)
EP (1) EP1802621B1 (de)
JP (1) JP2008517060A (de)
AT (1) ATE430746T1 (de)
DE (1) DE602005014375D1 (de)
ES (1) ES2326827T3 (de)
WO (1) WO2006044821A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ547990A (en) * 2003-12-22 2010-04-30 Smithkline Beecham Cork Ltd CRF receptor antagonists and methods relating thereto
GB0519957D0 (en) * 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US8088779B2 (en) * 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
EP2601192B1 (de) * 2010-08-04 2017-03-01 Takeda Pharmaceutical Company Limited Kondensierte heterocyclische verbindungen
WO2012124782A1 (ja) 2011-03-16 2012-09-20 武田薬品工業株式会社 縮合複素環化合物
JP6585625B2 (ja) 2014-01-21 2019-10-02 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト
WO2017121308A1 (en) * 2016-01-11 2017-07-20 Chongqing Fochon Pharmaceutical Co., Ltd. Fused pyridine compounds, compositions and methods of use
US10034861B2 (en) * 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
JOP20190126A1 (ar) 2016-12-22 2019-05-28 H Lundbeck As بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
EA037544B1 (ru) * 2017-04-04 2021-04-12 Х. Лундбекк А/С ПРИМЕНЕНИЕ 1H-ПИРАЗОЛО[4,3-b]ПИРИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE1
LT3723807T (lt) * 2017-12-14 2021-12-10 H. Lundbeck A/S Kombinuoti gydymai, apimantys 1h-pirazolo[4,3-b]piridinų vartojimą
AR113926A1 (es) * 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
US11535611B2 (en) 2017-12-20 2022-12-27 H. Lundbeck A/S Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors
US10766893B2 (en) * 2017-12-20 2020-09-08 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
TW201927784A (zh) 2017-12-20 2019-07-16 丹麥商Ｈ 朗德貝克公司 作為pde1抑制劑之大環
CA3094609A1 (en) * 2018-04-09 2019-10-17 Raqualia Pharma Inc. Fused cyclic urea derivatives as crhr2 antagonist
MA54395A (fr) 2018-12-07 2022-03-16 Neurocrine Biosciences Inc Antagoniste du récepteur crf1, formulations pharmaceutiques et formes solides correspondantes pour le traitement de l'hyperplasie surrénalienne congénitale
CN114502162B (zh) 2019-09-27 2025-03-28 纽罗克里生物科学有限公司 Crf受体拮抗剂及使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0765327B1 (de) * 1994-06-16 1999-07-21 Pfizer Inc. Pyrazolo und pyrrolopyridine
TR199900389T2 (xx) * 1996-08-28 2000-06-21 Pfizer Inc. �kame edilmi� 6,5-hetero-bisiklik t�revleri.
WO1999045002A1 (en) * 1998-03-04 1999-09-10 Kyowa Hakko Kogyo Co., Ltd. Benzofuran derivatives
WO1999045007A1 (en) * 1998-03-06 1999-09-10 Janssen Pharmaceutica N.V. Crf antagonistic pyrazolo[4,3-b]pyridines
US6531475B1 (en) * 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
OA12050A (en) * 1999-09-30 2006-05-02 Neurogen Corp Certain alkylene diamine-substituted heterocycles.
WO2002088095A1 (en) * 2001-04-30 2002-11-07 Glaxo Group Limited Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
WO2002100863A1 (en) * 2001-06-12 2002-12-19 Glaxo Group Limited Corticotropin releasing factor antagonists
GB0117396D0 (en) * 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
DE60213851T2 (de) 2001-12-04 2007-09-13 F. Hoffmann-La Roche Ag Ringannelierte pyrazolderivate
ATE359782T1 (de) * 2003-01-16 2007-05-15 Sb Pharmco Inc Heteroaryl-substituierte pyrrol(2, 3- b)pyridin- derivate als crf-rezeptor-antagonisten
US20070021429A1 (en) * 2003-04-09 2007-01-25 Yves St-Denis Condensed n-heterocyclic compounds and their use as crf receptor antagonists
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
NZ547990A (en) * 2003-12-22 2010-04-30 Smithkline Beecham Cork Ltd CRF receptor antagonists and methods relating thereto
EP1697369A1 (de) * 2003-12-22 2006-09-06 SB Pharmco Puerto Rico Inc Crf-rezeptorantagonisten und diese betreffende verfahren
WO2006043950A1 (en) * 2004-10-20 2006-04-27 Smithkline Beecham Corporation Il-8 receptor antagonists

Also Published As

Publication number Publication date
US7652035B2 (en) 2010-01-26
WO2006044821A1 (en) 2006-04-27
US20080064719A1 (en) 2008-03-13
WO2006044821A8 (en) 2006-08-24
JP2008517060A (ja) 2008-05-22
EP1802621B1 (de) 2009-05-06
EP1802621A1 (de) 2007-07-04
ES2326827T3 (es) 2009-10-20
DE602005014375D1 (de) 2009-06-18

Similar Documents

Publication Publication Date Title
DE602005014375D1 (de) Crf-rezeptor-antagonisten und zugehörige verfahren
TW200626599A (en) CRF receptor antagonists and methods relating thereto
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
EA201070238A1 (ru) Соединения пиримидина
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
MX2007007220A (es) Compuestos de pirazolona como agonistas de receptor de glutamato metabotropico para el tratamiento de trastornos neurologicos y psiquiatricos.
CA2603830A1 (en) PYRIDINE [2,3-B] PYRAZINONES
MX2012008049A (es) Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,.
TW200718422A (en) 1,6-Dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
MX2010007392A (es) Antagonistas de trpa1.
EA200970302A1 (ru) Тиофенпиразолопиримидиновые соединения
MX2010007023A (es) Agonistas del receptor glucocorticoide sustituido de c20-c21.
TW200719886A (en) Dihydrobenzofuran derivatives and uses thereof
MX2010007391A (es) Antagonistas de trpa1.
MX2009005217A (es) Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos.
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
DE69903333D1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
IL182959A0 (en) Potentiators of glutamate receptors
PL1620425T3 (pl) Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu
IL206359A0 (en) Sulfonamides as orexin antagonists
WO2007064553A3 (en) Thiazole derivatives as cxcr3 receptor modulators
NO20063230L (no) CRF receptorantagonister og fremgangsmater for fremstilling derav
IL209629A0 (en) Pyrrolidin - 3 - ylmethyl - amine as orexin antagonists
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties